Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (BHC) delivers innovative healthcare solutions across gastroenterology, dermatology, and eye health through brands like Bausch + Lomb and Salix Pharmaceuticals. This page provides investors and industry professionals with a comprehensive repository of official company announcements and market-relevant updates.
Key resources include: earnings reports, regulatory filings, product launch announcements, and partnership developments. All content is sourced directly from BHC’s verified communications to ensure accuracy and timeliness.
Regularly updated with press releases spanning therapeutic advancements, financial results, and operational milestones. Bookmark this page to monitor BHC’s strategic initiatives within the global pharmaceutical landscape.
Bausch Health reported strong Q1 2025 financial results with consolidated revenues of $2.26 billion, marking a 5% increase year-over-year. The company achieved its eighth consecutive quarter of growth, with a 6% revenue increase and 14% Adjusted EBITDA growth for Bausch Health excluding Bausch + Lomb.
Key highlights include:
- Salix segment grew 9% to $542 million
- Solta Medical segment surged 28% to $113 million
- Bausch + Lomb segment increased 3% to $1.14 billion
Despite posting a GAAP net loss of $58 million, the company successfully completed a $7.9B refinancing in April to extend maturities. Bausch Health maintained its full-year 2025 Revenue and Adjusted EBITDA guidance while updating its Adjusted Cash Flow from Operations guidance to reflect higher interest expenses.
Bausch Health and its aesthetic business Solta Medical have received Health Canada clearance for their Thermage FLX system, an advanced non-invasive radiofrequency skin tightening technology.
The fourth-generation Thermage FLX system offers several key improvements:
- 25% faster treatments with a larger 4.0 cm² treatment tip
- Enhanced patient comfort through integrated vibration and cooling
- Smart AccuREP technology that adjusts RF energy based on skin impedance
- Ergonomic handpiece design for improved provider workflow
- Versatile applications for face, eyes, and body treatments
This approval marks a significant milestone for Bausch Health's aesthetic business growth in Canada, bringing the same advanced technology already used in leading aesthetic clinics worldwide to Canadian providers and patients. The system builds on Thermage's 20-year legacy of trusted non-invasive skin tightening solutions.
Bausch Health (NYSE:BHC) has announced the launch of Fraxel FTX™, the next generation of skin resurfacing technology, at the ASLMS 2025 Conference in Orlando. The product will be initially rolled out to US dermatologists and aesthetic professionals, with global expansion planned in coming months.
The new Fraxel FTX™ features dual wavelength fractional laser technology (1550nm and 1927nm), targeting both superficial and deeper skin layers. Key improvements include:
- 20% reduction in handpiece weight and size with integrated cooling
- Intelligent Optical Tracking® with AccuTRAC™ for efficient treatment delivery
- Redesigned console with integrated arm
- New color touch screen interface for personalized treatments
The device is indicated for various dermatological procedures including skin resurfacing, treatment of dyschromia, actinic keratosis, melasma, wrinkles, and scars.
Bausch Health (NYSE:BHC) has filed a supplement to its April 2, 2025 proxy statement, revealing that Carl Icahn and affiliates have acquired cash-settled equity swaps for approximately 90.7 million common shares (24.6%), in addition to their 34.7 million beneficially owned shares (9.4%). This brings Icahn's total economic interest to approximately 34% of outstanding shares.
The company's Board directed a review of Icahn's swap positions and John Paulson's bond holdings. Icahn's swaps were accumulated between May 2021 and September 2023, with a February 2028 maturity date. Paulson, the Board Chairman, holds $50 million in Bausch Health bonds and plans to dispose of these securities to avoid potential conflicts of interest.
In response, Bausch Health implemented a shareholder rights plan (SRP) on April 14, 2025, designed to prevent any entity from acquiring 20% or more of outstanding shares without complying with permitted exemptions.
Bausch Health (NYSE/TSX: BHC) and its subsidiary Salix Pharmaceuticals announced a significant legal victory as the U.S. District Court for the District of Columbia ruled in favor of FDA, Salix, and Teva in a lawsuit filed by Norwich Pharmaceuticals.
The court denied Norwich's motion for preliminary injunction regarding its ANDA for XIFAXAN® (rifaximin) 550 mg. Norwich had challenged FDA's decision to issue tentative approval for their application and the agency's handling of Teva's 180-day exclusivity period. Norwich argued that the FDA's determination would prevent them from marketing their products until at least June 29, 2028, assuming Teva launches its rifaximin product in January 2028.
The District Court granted summary judgment supporting FDA, Salix, and Teva's position, effectively closing the case.
Bausch Health (NYSE:BHC)(TSX:BHC) has announced the adoption of a shareholder rights plan (SRP) effective April 14, 2025. The plan is designed to ensure fair and equal treatment of shareholders during any unsolicited takeover attempts or control acquisitions, including 'creeping' takeovers.
Under the SRP, one right will be attached to each outstanding common share. If triggered, rights holders (except the acquiring party) can purchase additional company shares at a significant discount to market price. The plan includes provisions for 'Permitted Bids' that wouldn't activate the SRP.
The Board emphasizes that this adoption is not in response to any specific takeover proposal or threat. The SRP requires Toronto Stock Exchange acceptance and shareholder ratification within six months of the effective date. If shareholders don't approve the plan, it will terminate along with all outstanding rights.
Bausch Health (NYSE:BHC) and its dermatology division Ortho Dermatologics have launched their 2025 ASPIRE HIGHER Scholarship Program, offering six scholarships worth up to $10,000 each to students affected by dermatologic conditions.
The program includes three Undergraduate Scholar Awards for students pursuing undergraduate or vocational/technical degrees, and three Graduate Scholar Awards for graduate-level students. Applications are open through June 11, 2025, with winners to be announced in July 2025.
Applicants must submit an online application, write an essay about their experience with a diagnosed dermatologic condition and their healthcare provider's role, and provide two reference letters. The scholarships support students attending or applying to two- or four-year colleges, universities, or advanced vocational/technical schools for the 2025-2026 academic year.
Bausch Health, Canada Inc. has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for public drug plan coverage of CABTREO, their triple-combination topical treatment for acne vulgaris. The agreement will enable coverage through all Canadian government drug plans, including provincial, territorial, and federal programs.
CABTREO is the first Health Canada-approved triple-combination topical acne treatment combining three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The prescription gel, administered once daily, is indicated for patients 12 years and older.
Bausch Health (NYSE/TSX: BHC) and its gastroenterology unit Salix Pharmaceuticals have launched 'IBS Symptoms Aren't Black and White: Living in the Gray,' a storytelling campaign for IBS Awareness Month in April 2025.
The initiative aims to highlight the complexities of Irritable Bowel Syndrome (IBS), a condition affecting up to 10% of the global population. The campaign will share patient stories on LinkedIn, focusing on how IBS impacts physical, emotional, social, and professional well-being.
Salix has partnered with the International Foundation for Gastrointestinal Disorders (IFFGD) to reduce stigma and encourage open discussions about IBS symptoms, including diarrhea, difficult bowel movements, abdominal pain, bloating, and urgency. The campaign seeks to empower patients to seek appropriate care and improve how IBS is perceived, diagnosed, and treated.
Bausch Health (NYSE/TSX: BHC) has scheduled the release of its first quarter 2025 financial results for Wednesday, April 30, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the quarterly performance and provide a business update. All related materials will be accessible through the Investor Relations section of Bausch Health's website before the call begins.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
